ROCKVILLE, Md & BOSTON (PRWEB)
March 19, 2020

An AIM-HI Accelerator Fund portfolio company exclusively focused on the development of pediatric cancer therapeutics has garnered recognition and additional funding. Oncoheros Biosciences Inc. won the Squinto-LePera Award at the Lyfebulb-Helsinn Cancer Innovation Summit held in Monaco and secured up to $1.1 million in new investment from Dreamers Startup Ventures.

The international Squinto-LePera Award highlights promising oncology start-ups whose founders are themselves cancer patients, survivors or family members to those with the disease. Oncoheroes’ co-founders, CEO Ricardo Garcia and COO Cesare Spadoni, Ph.D., are both fathers touched by cancer. The company was one of the finalists invited to pitch to a judging panel of professionals in the cancer, healthcare and business communities assembled by Lyfebulb, a U.S. chronic disease management platform provider, and Helsinn, a Swiss pharmaceuticals company specializing in products mitigating cancer chemotherapy side effects.

Dreamers Startup Ventures, with offices in the U.S and Spain, is an early stage investor targeting biopharmaceutical and health care companies, as well as those in the artificial intelligence field that are focused on life sciences. It recognizes Oncoheroes’ strategy of focusing on pediatric oncology drugs, which offers hope for unmet needs of childhood cancer patients and regulatory advantages of speedier market access and lower development costs relative to therapeutic candidates for more common illnesses.

Oncoheroes was established in 2017 with an initial grant from the National Foundation for Cancer Research and seed investment in 2019 from AIM-HI. The company is led by a highly experienced management, research and regulatory team, with specialties in drug screening, discovery and early stage clinical trials. Its scientific advisory board includes Children’s Hospital of Philadelphia Children’s Oncology Chair Peter Adamson M.D., Ph.D., Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Experimental Therapeutics Director Steven Dubois, M.D., and Children’s Hospital of Los Angeles Basic and Translational Cancer Research and Blood Disease Section Head Lee Helman, M.D.

The start-up has built an active collaborative platform with international pediatric oncology networks and, in September 2019, in-licensed volasertib from Boehringer Ingelheim. The drug candidate, initially developed as a treatment for leukemia, is an inhibitor of the enzyme PLK1, which is known to be associated with various cancers. Independent academic groups have generated strong data in support of developing the compound for rhabdomyosarcoma and other pediatric cancer indications. Additional assets are being explored to fill out Oncoheroes’ pipeline.

“Oncoheroes is proud of receiving the 2020 Squinto-LePera Award and Dreamers Startup Ventures’ funding,” stated Mr. Garcia. “Like our partnership with and investment from the AIM-HI Accelerator Fund, they validate and build upon our goal of making a difference for pediatric cancer patients and their families.”

“I am happy to see the considerable progress made by Oncoheroes so far,” said Sujuan Ba, Ph.D., president and CEO of the AIM-HI Accelerator Fund. “Pediatric cancer is a scourge yet not many groups are funding it.”

“We must change this fact,” Dr. Ba continued. “I am gratified that others, such as Lyfebulb, Helsinn and Dreamers Startup Ventures, are joining AIM-HI in our efforts to make an impact toward saving children’s lives.”

About the AIM-HI Accelerator Fund

The AIM-HI Accelerator Fund is an independent 501(C)(3) non-profit organization, established with an initial grant from the National Foundation for Cancer Research with the vision to accelerate the translation of cancer drug discoveries by investing in seed-stage companies. It is a new paradigm through venture philanthropy to fund start-up oncology companies that commercialize innovative laboratory breakthroughs which can potentially save cancer patients’ lives. For more information, visit https://www.aim-hiaccelerator.org.

About Oncoheroes Biosciences Inc.

Oncoheroes is a biotech company exclusively focused on the discovery and development of better drugs for children and adolescents with cancer. Its vision is to deliver benefits to young cancer patients and create value in the process. The management team is formed by drug development and industry professionals in the U.S. and Europe. For more information, visit: https://www.oncoheroes.com.

Share article on social media or email:

EAGAN, Minn. (PRWEB)
March 19, 2020

The rapid spread of the novel coronavirus (COVID-19) has placed unique pressures on the hospital supply chain, forcing facilities to maintain a detailed picture of what inventory they have available, where it’s located, and how fast it’s moving – all of which is essential to treating the high volume of patients with COVID-19 symptoms. To help hospitals achieve this critical balance and to ensure health care providers have the proper personal protective equipment (PPE) to safely perform their jobs, Jump Technologies announced today it will temporarily open its inventory management platform to all hospitals at no cost to help facilities ensure they have the proper PPE and related COVID-19 supplies available for hospital workers.

“At times like this, it’s vitally important for hospitals to have the supplies their employees need to stay safe. To do this, they need a clear picture of PPE inventory so they understand the resources available to them and whether they are at risk of running out of essential supplies before their next shipment,” said John Freund, CEO of Jump Technologies. “Because we understand the challenges this pandemic creates for hospital supply chain, we are waiving our fees to ensure as many hospitals as possible have access to tools that will give them insight into high-demand supplies that are essential to their employees.”

According to Freund, the Jump Technologies solution runs in the cloud and does not require any special hardware, so it can be set up quickly and with no disruption to hospital operations. Supply chain staff can be up to speed on using the system with just a 30-minute training session. Key elements of the reporting tool include:

• Using JumpStock, hospitals can easily see where existing supplies are located (in hospital storage or in a warehouse); track consumption by department, clinic, or user; and forecast potential stockouts.
• The new solution does not require integration into the hospital ERP or EMR and does not require access to sensitive data such as patient information or pricing.
• Because it is a cloud-based solution, it is safe, simple, and secure for hospitals.

Hospitals and health systems can access the Jump Technologies solution by filling out a form at http://www.jumptech.com/covid19. A representative from Jump Technologies will contact the hospital to discuss setup options, configure the account, and upload data.

###

About Jump Technologies

Jump Technologies creates safe, simple, and cost-effective solutions that help hospitals reduce stockouts, overordering, and waste while increasing inventory turns and improving billing accuracy across a facility or system. The company’s JumpStock solution facilitates data-driven decision making that allows hospitals to save time, free up cash, and improve nurse satisfaction with supply chain. To learn more, visit http://www.jumptech.com or call (888) 373-7226. Follow Jump Technologies on LinkedIn and Twitter @JumpTechNews.

Share article on social media or email:

WASHINGTON (PRWEB)
March 19, 2020

Legal publisher Fastcase and partner HB Litigation Conferences today announced a journal partnership to provide firms with expert insights into emerging litigation. The new Journal of Emerging Litigation will be led by Managing Director and Founder of HB Litigation Conferences Tom Hagy, who was the former Publisher and Managing Editor of LexisNexis Mealey’s Litigation Reports. The Journal will be published by Full Court Press, the imprint of Fastcase.

“With many new areas of emerging litigation, from vaping and the emerging health crisis to privacy breaches to the in city invasion of e-scooters or the malodorous air pollution of hemp farms, our Docket Alarm service is in a unique position to track the filing data. We wanted to use this data to focus on new types of lawsuits and the experts who are leading the charge, before litigation completely unfolds. To do so, we have tapped a strong journalist and leader who can make sense of these new types of lawsuits and pick the best of the best to cover. Tom Hagy was the first and best choice for us,” noted Steve Errick, COO of Fastcase.

Publishing its first issue this summer, the journal’s focus will parallel Hagy’s career-long concentration on emerging areas of litigation, supported with the valuable filing data from Docket Alarm. He added, “Emerging Litigation has always been driven by word-of-mouth until the first few verdicts come in and then the race is on. When Law Street Media Editor-in-Chief David Nayer told me Juul lawsuits were averaging four filings a month in April 2019, and 240 a month in October, it underscored the predictive value of early activity among litigators. Working with the Law Street Media and Docket Alarm teams as they count and track emerging litigation at the filing level grants us a fantastic ability to jump ahead and cover litigation as it unfolds – now that’s emerging litigation data!”

“I am excited to work with an innovative, growing company like Fastcase,” Hagy said. “I have a passion for emerging areas of litigation and working with top lawyers from around the country to cover these cases, evaluate them, and share valuable insights with professionals in the legal and business communities.”

Law Street Media Editor-in-Chief David Nayer envisions the journal as a continuation of Fastcase’s legal news service and a must-have resource for firms embracing emerging litigation. “As exciting as it is to cover breaking litigation daily, we wanted to expand our capabilities by connecting the Law Street Media data pipeline with Full Court Press, transforming breaking news into practice and deeper analysis.”

“Our motto for Law Street is: Legal News Leads to Business,” Nayer said. “One sure way to drive business to a law firm is to know about emerging litigation first. With our Emerging Litigation Journal – our subscribers can be among the first to see litigation trends and how leading litigators are developing their legal analysis. This all supports growing a firm’s book of business. It’s the roadmap for rainmakers in small and large firms alike.”

Law Street Media’s Emerging Litigation Law Journal will be the third periodical produced by the expanding Fastcase imprint Full Court Press, the publishing arm of Fastcase. Like Full Court Press’s first two journals, RAIL: The Journal of Robotics, Artificial Intelligence & Law and AILA’s Immigration Law Journal, the new Journal of Emerging Litigation will be available in several mediums: print, eBook, PDF, and within the Fastcase legal research application as part of an enhanced Law Street Media subscription.

As part of the launch, Hagy will form an Editorial Board of advisors with respective industry litigation expertise, and work closely with the Docket Alarm and Law Street Media team to cover the most urgent new litigation trends of 2020 and beyond.

About Fastcase

Fastcase is a leading legal publisher that democratizes the law, making it more accessible to more people. Fastcase is a comprehensive research suite of primary law, treatises, legal blogs, analytics, workflow tools, and legal news. Founded in 1999, the service has more than 900,000 subscribers from around the world. Fastcase is an American company based in Washington, D.C. For more information, follow Fastcase on Twitter at @Fastcase or visit fastcase.com.

About HB Litigation Conferences

Tom Hagy founded HB Litigation Conferences LLC in 2008 to produce CLE conferences and webinars on dynamic areas of litigation within mass torts, class actions, insurance, and privacy law. To fill the need for white-label legal and business content, Hagy also founded Custom Legal Content LLC to serve a limited number of carefully selected clients. Hagy is former Managing Editor and Publisher of Mealey’s Litigation Reports (now part of LexisNexis) where he expanded a portfolio of litigation news and commentary reports on emerging areas, as well as a parallel conference operation. He is a former Vice President of Content at LexisNexis, where he led or participated in the development of rich content collections relating to jury verdicts and settlements; briefs, pleadings and motions; and expert witnesses.

Share article on social media or email:

CLIFFSIDE PARK, N.J. (PRWEB)
March 19, 2020

Cliffside Park, NJ luxury condo development One Park has announced a new array of measures to protect its residents against the Coronavirus pandemic. Among them, the top priorities are taking precautions around visitors, disinfecting the property frequently and closing the building’s amenities while also briefing residents on the full extent of protocol being implemented.

The precautionary measures being taken to protect tenants at One Park are as follows:

Effective today, all amenity spaces in the property would be closed until further notice.

All visitors to the building must register with the front desk and will be provided hand sanitizer.

Daily disinfecting will take place for all common areas, surfaces, elevators, fountains and walls.

The sales office for the property is closed until further notice. All showings will be by private appointment only from 10 am – 4 pm Daily.

One Park has briefed its residents on its crisis response plan and is focused on providing the safest environment possible for tenants and employees of the building. Continuous updates will be provided on any additional measures that need to be taken as well as the progression of the outbreak.

One Park, the premiere luxury condominium development located in Bergen County’s Cliffside Park, offers fourteen stories with two hundred four upscale units featuring expansive views of the New York City skyline and Hudson River. Units offer spacious living arrangements featuring from one to four bedrooms and up to 2,983 square feet of living space. Interior spaces boast gourmet kitchens with chef-caliber appliances, sanctuary-like bedroom suites, and spa-inspired master suite baths. One Park is a recognized leader in world class architecture and dramatic views in the Bergen County community.

One Park residents enjoy privileged amenities and a short commute to and from New York City. With amenities that rival New York City luxury buildings, including an outdoor movie theater, fitness center, golf simulator, children’s playroom, and pet spa, residents want for nothing. One Park residents have attentive twenty-four-hour doorman service and two options to accommodate their automobiles, including the recent addition of a luxury vehicle garage designed explicitly for low chassis vehicles like the Lamborghini and Ferrari. A resident-only shuttle service is also an option.

About DMG Investments

Headquartered in New York City at 100 Wall Street, DMG Investments LLC (“DMG”) was established in 2013.

DMG focuses on real estate acquisitions, development and management as well as financing. Leveraging the expertise of a team of dedicated real estate professionals with decades of experience creating and adding value for investors, DMG has amassed a portfolio of best-in-class assets across the US in dynamic markets in New York, New Jersey, Texas, Tennessee, Wisconsin, and South Carolina.

As the portfolio continues to grow, DMG is dedicated to providing amenities and services that enhance the livability of each project be it in the student housing, traditional multifamily or condominium sector. In the years to come, the goal of DMG is to become a global real estate enterprise with a world-class reputation for sustainable development and a business philosophy that emphasizes the importance of delivering value for investors, owners and residents.

Share article on social media or email: